Roddy Paul, Goiri Javier, Flevaud Laurence, Palma Pedro Pablo, Morote Silvia, Lima Nines, Villa Luis, Torrico Faustino, Albajar-Viñas Pedro
Médecins Sans Frontières Spain, Barcelona, Spain.
J Clin Microbiol. 2008 Jun;46(6):2022-7. doi: 10.1128/JCM.02303-07. Epub 2008 Apr 9.
Laboratory and clinical diagnostic classification of seropositive individuals, followed by treatment and supportive therapy, is an established component of Chagas' disease control in areas where this disease is endemic. However, most Chagas' disease patients live in remote areas where neither equipped laboratories nor skilled human resources are widely available. Employing a rapid diagnostic test (RDT), when using whole blood samples, is the best option for Chagas' disease control. A high sensitivity and specificity for the Chagas Stat-Pak RDT (Chembio Diagnostic Systems, Inc., Medford, NY) has been reported for assays using serum and plasma, but its validity for the detection of antibodies to Trypanosoma cruzi infection in whole blood is unknown. This cross-sectional study measured the sensitivity and specificity of the Chagas Stat-Pak with whole blood, using conventional serological assays for comparison. The interobserver reliability in the interpretation of the Chagas Stat-Pak results and "ease-of-use" criterion needed to perform the Chagas Stat-Pak and conventional assays were also measured. The Chagas Stat-Pak yielded a high specificity (99.0%, 95% confidence interval [CI] = 98.4 to 99.4%) but a relatively low sensitivity (93.4%, 95% CI = 87.4 to 97.1%). The interobserver reliability was excellent (kappa [n = 1,913] = 0.999, P < 0.0001), and the quantified ease-of-use criterion suggested that the RDT is simple to perform. Despite the attributes of the Chagas Stat-Pak, it is not an ideal diagnostic test for the population investigated in the present study due to its relatively low sensitivity and high cost. The RDT manufacturer is called upon to improve the test if the international community hopes to make progress in controlling Chagas infections in areas where this disease is endemic.
对血清反应呈阳性的个体进行实验室和临床诊断分类,随后进行治疗和支持性治疗,是在恰加斯病流行地区控制该疾病的既定组成部分。然而,大多数恰加斯病患者生活在偏远地区,那里既没有配备齐全的实验室,也没有广泛可用的专业人力资源。使用全血样本进行快速诊断检测(RDT)是控制恰加斯病的最佳选择。据报道,恰加斯Stat - Pak RDT(Chembio诊断系统公司,纽约州梅德福)用于血清和血浆检测时具有高灵敏度和特异性,但它在全血中检测克氏锥虫感染抗体的有效性尚不清楚。这项横断面研究使用全血检测了恰加斯Stat - Pak的灵敏度和特异性,并与传统血清学检测进行比较。还测量了恰加斯Stat - Pak结果解读中的观察者间可靠性以及进行恰加斯Stat - Pak和传统检测所需的“易用性”标准。恰加斯Stat - Pak具有高特异性(99.0%,95%置信区间[CI] = 98.4%至99.4%),但灵敏度相对较低(93.4%,95% CI = 87.4%至97.1%)。观察者间可靠性极佳(kappa[n = 1,913] = 0.999,P < 0.0001),量化的易用性标准表明该快速诊断检测操作简单。尽管恰加斯Stat - Pak有这些特性,但由于其相对较低的灵敏度和较高的成本,对于本研究中所调查的人群而言,它并非理想的诊断检测方法。如果国际社会希望在恰加斯病流行地区控制该疾病方面取得进展,呼吁快速诊断检测制造商改进该检测方法。